Skip to main content

Table 1 Determinations by ELISA for each factor analyzed, with the range of values observed among positive samples, the number of positive samples in each group, and the detection limit of assays

From: Adipose tissue-derived extracellular fraction characterization: biological and clinical considerations in regenerative medicine

ELISA targets AT-Ex Plasma Detection limit
No. of positive samples Mean ± SD Range No. of positive samples Mean ± SD Range
bFGF 20/20 4430.7 ± 3102.9 1015.5–11476.0 0/20 ND ND 50 pg/ml
EGF 20/20 35.3 ± 21.0 15.5–63.1 20/20 562.5 ± 186.1 160.8–772.6 26 pg/ml
Epo 20/20 5.24 ± 1.87 2.26–8.6 20/20 7.83 ± 4.9 3.0–16.9 0.17 mlU/ml
GM-CSF 17/20 2.17 ± 1.38* 01.6–4.4* 20/20 10.2 ± 11.0 2.0–26.6 0.6 pg/ml
KGF 17/20 486.3 ± 279.5* 176.4–1052.0* 8/20 602.4 ± 612.6* 150.0–1299.6 4.0 pg/ml
SCF 20/20 5.79 ± 2.82 1.6–10.4 0/20 ND ND 0.45 ng/ml
NGF 20/20 95.2 ± 9.04 84.0–112.0 0/20 ND ND 19.5 pg/ml
VEGF-A 20/20 2274.7 ± 964.7 315.8–2885.0 17/20 337.8 ± 243.3* 0–775.3* 7.9 pg/ml
α-MSH 20/20 2.16 ± 1.13 0.46–3.91 14/20 0.067 ± 0.043* 0.029–0.146 0.039 ng/ml
Wnt3a 20/20 21.6 ± 2.4 9.82–28.0 4/20 0.50 ± 0.45* 0.08 ± 1.25 0.054 ng/ml
Wnt10b 19/20 4.0 ± 1.26* 0.24–4.25 0/20 ND ND 0.058 ng/ml
  1. bFGF basic fibroblast growth factor, EGF epidermal growth factor, ELISA enzyme-linked immunosorbent assay, Epo erythropoietin, GM-CSF granulocyte/macrophage colony-stimulating growth factor, KGF keratinocyte growth factor, MSH melanocyte stimulating hormone, ND not determined, NGF nerve growth factor, SCF stem cell factor, VEGF vascular endothelial growth factor, Wnt wingless type
  2. *mean values were calculated only with positive samples whereas range of concentration include negative sample (negative=0)